Navigation Links
Sequella and NIH Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications
Date:11/16/2009

Anti-Fungal, Additional Mycobacterial Indications Among Those Targeted

ROCKVILLE, Md., Nov. 16 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.

SQ109, currently completing a Phase IB safety study in humans under its original tuberculosis IND, is a new chemical entity with broad antibiotic potential. It was co-discovered by scientists at Sequella and at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, under an earlier Cooperative Research and Development Agreement. Sequella previously negotiated from NIH worldwide exclusive rights for SQ109's use against tuberculosis.

The new agreement will allow Sequella to pursue additional infectious disease indications targeting fungi and a variety of nontubercular Mycobacteria.

Dr. Carol Nacy, CEO of Sequella, said, "We see tremendous promise in the future of SQ109, both as part of a new tuberculosis regimen and as a therapeutic active against other infectious agents. IND-directed studies in support of these new indications are underway."

About SQ109

SQ109 is a new diamine antibiotic intended to replace one or more of the current first-line anti-TB drugs and simplify patient therapy. SQ109 was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows activity against drug sensitive and multi-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of TB. SQ109 is due to begin a Phase 1B study to assess safety and pharmacokinetics of multiple doses of SQ109 in healthy subjects.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

About NIAID and NIH

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law. The content of this release does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

SOURCE Sequella, Inc.


'/>"/>
SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
2. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
3. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
4. Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
5. Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. Vet-Stem and Central Veterinary Research Labs of Dubai Sign Exclusive License
11. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- China Cord Blood Corporation (NYSE: CO ) ... provider of cord blood collection, laboratory testing, hematopoietic stem cell ... of its 2016 Annual General Meeting, which was held on ... . At the Annual General Meeting, ... Huazhen LLP as the independent auditors of the Company for ...
(Date:12/9/2016)... December 9, 2016 According to a new ... Probe, Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, DNA, NGS, ... published by MarketsandMarkets, the global market is expected to reach USD ... a CAGR of 10.6% during the forecast period. ... ...
(Date:12/8/2016)... , Dec. 8, 2016 This report analyzes ... Product Segments: Acid Based (Humic, Amino, & Fulvic), Extract Based, ... the following Crop Types: Ornamental & Turf, Row Crops, and ... Canada , Japan , ... Latin America , and Rest of World. ...
(Date:12/8/2016)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... immunotherapies, today announced financial results for the fiscal ... delivering on our commitment to address an unmet ... are pleased with the early clinical response data ... are focused on advancing our lead program – ...
Breaking Biology Technology:
(Date:11/17/2016)... 2016  AIC announces that it has just released a new white paper authored ... scale-out plus high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
Breaking Biology News(10 mins):